Portfolio revaluation flips MLN to a NZ$11.6m HY23 loss

What changed

The headline reversal is driven by portfolio revaluation rather than trading operations. Reported revenue moved from NZ$6.3m in HY22 to negative NZ$9.4m in HY23, a NZ$15.7m swing consistent with an investment company booking fair-value losses. PBT fell from NZ$4.2m to negative NZ$10.6m (-354.2%) and NPAT from NZ$3.6m to negative NZ$11.6m (-421.4%).

Underneath the loss, the operating cash picture improved: net cash inflow from operating activities rose 42.5% to NZ$7.5m, and the closing cash balance lifted to NZ$5.5m from NZ$4.5m. Dividend income received held roughly steady at NZ$0.2m.

The balance sheet shrank in line with the mark-down. Total assets fell 33.0% to NZ$163.0m and total equity fell 33.1% to NZ$161.9m, while total liabilities were essentially unchanged at NZ$1.1m. The declared interim dividend of 1.66 cps is 33.3% below the 2.49 cps comparative.

What matters

• The loss is a portfolio mark, not an operating break. PBT and NPAT moved together (PBT-to-NPAT gap of 67.2pp is purely a tax effect at a 9.1% implied rate versus 13.8% prior), and no discontinued operation is disclosed. The read-through is that the HY23 loss is almost entirely driven by fair-value movements in the investment portfolio.
• Cash generation diverged from accounting earnings. Operating cash inflow of NZ$7.5m (up 42.5%) against an NPAT loss of NZ$11.6m reinforces that the P&L hit is non-cash revaluation, and it leaves the fund with more cash on hand than a year ago.
• Capital base has contracted sharply. Equity down NZ$80.2m year on year reduces the NAV from which future distributions and management activity are sized, and the interim dividend has been cut by a third in lockstep.

Expectations

No forward target, forecast NAV, or formal guidance is provided. Second-half shape context is of limited use here because FY22 itself carried large portfolio losses (full-year revenue of negative NZ$58.5m, NPAT of negative NZ$60.4m), making HY/FY ratios non-informative for a mark-to-market vehicle. Annualising HY23 revenue to negative NZ$18.8m is materially less negative than FY22's negative NZ$58.5m, but that comparison is directional only and says nothing about the path of markets in the second half. The release does not support any view on portfolio positioning, benchmark performance, or discount/premium to NAV.

Quality of result

The operating cash result looks durable in character — dividend income was stable and cash inflows grew — but it is not large enough to offset the portfolio revaluation driving the loss. The PBT-to-NPAT gap is tax, not a one-off item, so PBT of negative NZ$10.6m is the cleaner read and it is genuinely negative.

Working capital is a minor flag rather than a core issue: trade receivables rose to NZ$0.8m from NZ$0.2m, lifting receivable days to roughly 15.3 from 4.8, though absolute amounts are immaterial to a NZ$162m asset base. No non-recurring items, non-GAAP reconciliations, or capex figures were disclosed, so there is no adjusted earnings construct to separate from reported.

Unresolved

• What were the underlying portfolio drivers (geography, sector, specific holdings) of the NZ$15.7m revenue swing, and how has NAV moved post balance date?
• How does the 1.66 cps interim sit within the stated distribution policy, and what is the full-period dividend intent given the 33.3% cut versus HY22's interim?
• What explains the drop in the effective tax rate from 13.8% to 9.1% — imputation credit mix, deferred tax on unrealised losses, or something else?
• Are there any gross borrowings or derivative exposures? None were disclosed, but the filing does not explicitly confirm a debt-free position.

This briefing cannot assess portfolio composition, benchmark-relative performance, or the share price discount/premium to NAV, none of which are provided in the release.

Key metrics

Analytical metrics

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.